Keyphrases
Cancer Immunotherapy
100%
Antibody Conjugates
100%
Nanogel
100%
Immune Checkpoint Inhibitors
100%
Bispecific Antibody
80%
Monoclonal Antibody
60%
Tumor
20%
Tumor Site
20%
Luciferase
20%
Anti-tumor Response
20%
Cancer Cells
20%
Acrylic Acid
20%
Breast Cancer Cells
20%
Solid Tumors
20%
Poly(N-isopropylacrylamide) (PNIPAM)
20%
Immune System
20%
Anticancer Effect
20%
Metastatic Breast Cancer
20%
Syngeneic
20%
Triple-negative Breast Cancer
20%
Conventional Treatment
20%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
20%
Treatment Costs
20%
Programmed Death-ligand 1 (PD-L1)
20%
Multiple Antibodies
20%
Antibody Protein
20%
Michigan Cancer Foundation-7
20%
Medicine and Dentistry
Cancer Immunotherapy
100%
Antibody Conjugate
100%
Immune Checkpoint Inhibitor
100%
Bispecific Antibody
100%
Monoclonal Antibody
75%
Cancer Cell
50%
Neoplasm
50%
Malignant Neoplasm
25%
Breast Cancer
25%
In Vitro
25%
Health Care Cost
25%
Acrylic Acid
25%
Immune System
25%
Triple Negative Breast Cancer
25%
Luciferase
25%
Solid Malignant Neoplasm
25%
CTLA-4
25%
Protein Antibody
25%
Programmed Death 1 Ligand 1
25%
Protein A
25%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immunotherapy
100%
Nanogel
100%
Antibody Conjugate
100%
Immune Checkpoint Inhibitor
100%
Bispecific Antibody
80%
Monoclonal Antibody
60%
Neoplasm
40%
Breast Cancer
20%
Luciferase
20%
Solid Malignant Neoplasm
20%
Acrylate
20%
Triple Negative Breast Cancer
20%
Protein Antibody
20%
Programmed Death 1 Ligand 1
20%
Protein A
20%
Cytotoxic T Lymphocyte Antigen 4
20%